

## [Linezolid](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines](#)

ATC codes: [J01XX08](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Linezolid

Medicine type

Chemical agent

Antibiotic groups

[RESERVE](#)

List type

Core

Additional notes

Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

Formulations

**Oral > Solid > dispersible tablet:** 150 mg (scored) (EMLc)

**Oral > Solid > tablet:** 600 mg

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Read more [about patents](#).

Wikipedia

[Linezolid](#)

DrugBank

[Linezolid](#)

Summary of evidence and Expert Committee recommendations



The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.